Leerink raises target for McKesson stock to USD 1,070.00

Published on 10/16/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 7.70 percent to USD 105.38 billion in the first quarter. McKesson stock gets a USD 44.20-45.00 fiscal 2027 earnings outlook.

Target increase and operating scale

Leerink Partners raised its McKesson target to USD 1,070.00 on October 7, 2026.
First-quarter revenue reached USD 105.38 billion, up 7.70 percent year over year.
McKesson stock traded at EUR 888.20 at 10:01 a.m. CEST at Lang & Schwarz on October 16, 2026.

Draufsicht auf Aktienzertifikat, ISIN-Karte, Stethoskop und Tabletten auf Holztisch — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte US58155Q1031 illustriert eine Investition in McKesson Corporation im Gesundheitswesen heute, Illustration mit AI erstellt.

McKesson (ISIN US58155Q1031) became the subject of a Leerink Partners target increase to USD 1,070.00 from USD 1,030.00 on October 7, 2026, according to MarketBeat. At Lang & Schwarz, the euro quote was EUR 888.20 on October 16, 2026 at 10:01 a.m. CEST.

What does the target imply?

The latest US primary-market price was USD 998.64 on the NYSE on October 15, 2026 at 4:00 p.m. ET. Against that price, the USD 1,070.00 target lies 7.14 percent above the last quoted level. The comparison uses the same currency and keeps the analyst view separate from the German euro quote.

McKesson's operating scale remains central to the valuation case. In the first quarter of fiscal 2027, revenue reached USD 105.38 billion, compared with USD 97.83 billion in the year-earlier quarter, while net income attributable to McKesson fell to USD 614.00 million from USD 784.00 million, according to MarketBeat. Adjusted fiscal 2027 earnings guidance stands at USD 44.20-45.00.

Three developments set the timeline

On August 5, 2026, McKesson reported first-quarter revenue of USD 105.38 billion and adjusted earnings per share of USD 9.93, according to MarketBeat. On October 6, 2026, McKesson agreed to invest approximately USD 1.40 billion for a 49 percent stake in Option Care Health, within a transaction valued at approximately USD 5.80 billion, according to McKesson. On October 7, 2026, Leerink Partners raised its target from USD 1,030.00 to USD 1,070.00.

Which dates come next?

McKesson is scheduled to report second-quarter fiscal 2027 results on November 4, 2026, according to Simply Wall St. The Option Care transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals, according to McKesson.

Stock price and valuation context

McKesson stock traded at EUR 888.20 at Lang & Schwarz on October 16, 2026 at 10:01 a.m. CEST. The NYSE quote had last stood at USD 998.64 on October 15, 2026, while the 52-week range was USD 723.68 to USD 1,003.21.

The further course of trading is shown by the continuously updated real-time quote of McKesson stock.